Sometimes getting a new drug to market is a relatively straight line, but sometimes it’s a winding road. GSK’s Blenrep (belantamab mafodotin) for multiple myeloma falls into the latter category, having been removed from the market after accelerated approval thanks to some bad Phase 3 data.
But at ASCO this year, that bad luck turned around with a new study that shows the drug is powerfully effective in the right combination - to the tune of a 48% improvement in progression-free survival.
At the conference in Chicago, pharmaphorum editor-in-chief Jonah Comstock met with Dr Suzanne Trudel, the principal investigator on the redemptive DREAMM-8 study. In the video below, Trudel outlines the goals and results of the study and talks about the effect it’s likely to have on physicians who treat multiple myeloma.
They also discuss some of the major trends of the conference, like the saturation of impressive antibody-drug conjugate data across therapeutic areas. Check out the interview below.
Subscribe to the pharmaphorum KZread channel for in-depth conversations with innovators across healthcare: / @pharmaphorum
Join us on Twitter for the latest news, features, event coverage, and discussions: / pharmaphorum
And for everything, everywhere, all at once, visit our official site: pharmaphorum.com/